A Prospective Study of Thymectomy and Serum Acetylcholine Receptor Antibodies in Myasthenia Gravis
C. Warren Olanow, Andrew S. Wechsler, Allen D. Roses
Abstract
C. Warren Olanow, Andrew S. Wechsler, Allen D. Roses
Abstract
Forty-seven consecutively presenting myasthenia gravis (MG) patients with generalized weakness were treated according to a standardized prospective protocol. All patients underwent a sternal splitting "total" thymectomy. Medical status before surgery was optimized by plasmapheresis without immunosuppression. Medications were avoided or discontinued whenever possible. All patients were improved. At the time of latest follow-up 83% were free of generalized weakness and 61% were on no medications. There was no significant change in Acetylcholine Receptor Antibody (AChR-AB) titer. The following conclusions were made: (1) thymectomy is an effective therapy for MG, (2) additional medications are not necessary in the majority of patients, and (3) a reduction in the AChR-AB titer is not essential for clinical benefit.
OpenAlex reports 92 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Forty-seven consecutively presenting myasthenia gravis (MG) patients with generalized weakness were treated according to a standardized prospective protocol. All patients underwent a sternal splitting "total" thymectomy. Medical status before surgery was optimized by plasmapheresis without immunosuppression. Medications were avoided or discontinued whenever possible. All patients were improved. At the time of latest follow-up 83% were free of generalized weakness and 61% were on no medications. There was no significant change in Acetylcholine Receptor Antibody (AChR-AB) titer. The following conclusions were made: (1) thymectomy is an effective therapy for MG, (2) additional medications are not necessary in the majority of patients, and (3) a reduction in the AChR-AB titer is not essential for clinical benefit.
Key concepts: Thymectomy, Medicine, Myasthenia gravis, Plasmapheresis, Immunosuppression, Prospective cohort study, Weakness, Titer